# Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

> **NCT02381080** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 26 (actual)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Erythromycin
- **DRUG:** Voriconazole

## Key facts

- **NCT ID:** NCT02381080
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-19
- **Primary completion:** 2016-06-24
- **Final completion:** 2016-06-24
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02381080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02381080, "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02381080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*